سعر لقاح مينسيفاكس التهاب سحائي 2023

Plain (non-conjugated) meningococcal polysaccharide vaccine against groups A, C, Y and W135; monodose powder and solvent for solution for injection.

• Active immunisation against invasive meningococcal disease caused by groups A, C, W135 and Y.Population: Children older than 2 years, adolescents and adultsPfizer Labeling (labeling.pfizer.com)

• Very common: headache, injection-site pain and redness, fatigue. Common: loss of appetite, irritability, drowsiness, gastrointestinal symptoms, fever, injection-site swelling. Uncommon: dizziness, urticaria, rash. Post-marketing: allergic reactions including anaphylaxis, angioneurotic oedema, arthralgia, influenza-like symptoms.International label, same product · Pfizer Labeling (labeling.pfizer.com)

• Hypersensitivity to the active substances or excipients, or after previous administration of Mencevax ACWY. Postpone in acute severe febrile illness (a minor infection is not a contraindication).International label, same product · Pfizer Labeling (labeling.pfizer.com)

• Appropriate treatment for anaphylaxis must be readily available; syncope may occur around vaccination, so procedures to avoid injury are needed.International label, same product · Pfizer Labeling (labeling.pfizer.com)
• Groups C, W135 and Y polysaccharides are poorly immunogenic under 24 months; protection is limited to groups A, C, W135 and Y and may be reduced in immunocompromised subjects. Group C polysaccharide may induce hyporesponsiveness to further group C doses.International label, same product · Pfizer Labeling (labeling.pfizer.com)
• May cause drowsiness or dizziness affecting the ability to drive or operate machinery.International label, same product · Pfizer Labeling (labeling.pfizer.com)

• Other injectable vaccinesNo data on concomitant administration; if unavoidable, use different injection sites. Do not mix with other medicinal products.Pfizer Labeling (labeling.pfizer.com)

• Limited data in pregnancy; use only when clearly needed and the possible advantages outweigh potential risks to the foetus.International label, same product · Pfizer Labeling (labeling.pfizer.com)
• Unknown whether excreted in human milk; use during breast-feeding only when advantages outweigh potential risks.International label, same product · Pfizer Labeling (labeling.pfizer.com)

English text not available for this section.